Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions ; volume:22 ; number:1 ; day:2 ; month:9 ; year:2024 ; pages:1-19 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (2.9.2024), 1-19, 12.2024
- Urheber
-
Li, Linxue
Ye, Ruiwei
Li, Yingying
Pan, Hanyu
Han, Sheng
Lu, Yiming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05620-x
- URN
-
urn:nbn:de:101:1-2411172345097.139018779907
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Linxue
- Ye, Ruiwei
- Li, Yingying
- Pan, Hanyu
- Han, Sheng
- Lu, Yiming
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions
Recent advances of human tumor immunology and immunotherapy
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions
Recent advances of human tumor immunology and immunotherapy
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions